Divis Laboratories Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/54qhzpv11ypskxefp3r54hfz.pdf

Key Takeaways


Revenue & Margin Dynamics

Dr. Murali K. Divi: "I think from now whatever growth we are seeing, I think we should start saying, this is 0 and look at how we are going to grow from now."

Custom Synthesis & Contrast Media

Dr. Murali K. Divi: "We are working on number of projects with number of big pharmas in the small molecule segment... we cannot predict in which quarter, which blockbuster may happen."

Generic API & Carotenoid Segments


Peptide Building Blocks & New Therapies

Dr. Murali K. Divi: "It is not a waiting period because it is only a customer approval and we meeting customer's requirements on the impurity profile and that should lead to the business."

Capex & Capacity Expansion


Guidance & Commitments

CommitmentSpecificsTimeline
Quarterly revenue trajectoryMove toward Rs. 2,000 crores plus, then Rs. 2,200 crores per quarterNo date; "slow, steady, consistent"
Steady-state EBITDA margin30%, 35%-40% rangeSteady-state (no date)
MRI contrast media process readinessTotal process ready for scale-up, customer samplingEnd of current financial year
MRI contrast media commercial launchFilings and commercial launchOne year after process readiness
Kakinada commercializationAdvanced intermediates and KSM productionMid-FY25
Carotenoid capacity additionAdditional capacity at Unit-3 onlineQ1-Q2 of next financial year
Generic product basket expansion2-5 new products added each yearAnnual, ongoing
Growth outlook"Good growth, a double digit growth" barring COVID or unforeseen incidentsOver the coming years
Dr. Murali K. Divi: "Ours is, we don't jump, slow, steady, consistent, and debt free, these are our models."

Key Metrics

MetricQ1 FY24
Consolidated total income₹1,859 cr, vs ₹2,343 cr in Q1 FY23
Constant currency growth-29%
Material consumption39% of sales revenue, vs 42% in Q4 FY23
Profit before tax₹492 cr
Profit after tax₹356 cr
Forex gain₹3 cr, vs ₹56 cr gain in Q1 FY23
Exports share86% of revenue
Exports to Europe and US67% of revenue
Product mix (Generics : Custom Synthesis)60:40
Nutraceutical revenue₹178 cr
Capital work in progress₹389 cr, of which Kakinada project is ₹130 cr
Cash on books₹4,208 cr as of March 31, 2023
Receivables₹1,720 cr as of March 31, 2023
Inventories₹2,967 cr as of March 31, 2023
Dividend payout₹796 cr, scheduled September 2023
Carotenoid plant utilization90-95%
Unit-3 greenfield project phase 1 investment₹1,500 cr
Steady-state EBITDA margin guidance30%, 35%-40%